X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq: XFOR) has promoted Renato Skerlj, Ph.D., to Chief Scientific Officer. Dr. Skerlj, a co-inventor of the lead drug candidate mavorixafor, joined X4 in 2019 and has significantly contributed to the company's research efforts. His leadership is crucial as the company advances mavorixafor through clinical trials for WHIM syndrome and genetically-defined blood cancers. X4 continues to focus on therapies targeting the CXCR4 pathway for rare diseases, with ongoing global Phase 3 trials for mavorixafor.
X4 Pharmaceuticals (Nasdaq: XFOR) announced it will host a conference call on June 12, 2020, to discuss clinical efficacy and safety data from the ongoing Phase 2 trial of mavorixafor for WHIM syndrome. The data will be shared at the 25th European Hematology Association Annual Congress from June 11-14, 2020. Mavorixafor, a first-in-class treatment, is currently evaluated in a global Phase 3 trial for WHIM syndrome and in additional Phase 1b trials for other conditions. The conference call can be accessed via phone or webcast.
X4 Pharmaceuticals (Nasdaq: XFOR) announced an inducement award for new employees on May 29, 2020, as part of its 2019 Inducement Equity Incentive Plan. A total of 55,200 options to purchase common stock at an exercise price of $8.52 per share were granted. These options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment. X4 is known for developing therapies targeting CXCR4 pathway dysfunction, focusing on rare diseases, with its lead candidate, mavorixafor, currently in Phase 3 trials.